XaTek's series A financing round has brought in $9.1 million to further development of a device that can quickly analyze blood clotting ability with a single drop. The device, called ClotChip, will now be tested in clinical trials.
New research highlights the benefits of multianalyte assays with algorithmic analyses to guide treatment of women's health issues, including breast cancer and preeclampsia. MAAAs use an algorithm to combine two or more biochemical or molecular markers, as well as patient information and demographics, to provide a personalized risk assessment.
British and Australia researchers found that the acid inositol hexakisphosphate, or IP6, which is found in cells, is used by HIV to strengthen the capsid that shields the virus's genetic material. Single-molecule microscopy showed that the capsid broke down within minutes without IP6, according to the study in eLife.
Disease-carrying ticks, including those that spread Lyme disease and babesiosis, were identified in 83 counties in 24 states where they had not been found before in a study of 16,000 ticks collected between January 2016 and August 2017. "People should be aware of ticks and tick-borne disease, even when they may think there's not a recorded incidence of a tick in a county," said Nate Nieto, an author of the study in PLOS One.
BioSight of Israel has gained clearance from the Israeli Ministry of Health and the US FDA for a Phase IIb trial of its treatment candidate for patients with acute myeloid leukemia who cannot receive standard chemotherapy. The trial will be conducted at 25 centers in the US and Israel.
French researchers found no significant difference in overall survival among 418 patients with acute myeloid leukemia who received either a donor lymphocyte infusion or a second allogeneic hematopoietic cell transplant, according to a study in the journal JAMA Oncology. The study also showed improved survival outcomes among those in complete remission and those who had prior chronic graft-versus-host disease.
Takeda's Ninlaro, or ixazomib, reportedly met its primary endpoint of extending progression-free survival as a single-agent maintenance therapy versus placebo in 656 multiple myeloma patients who had undergone induction therapy supported by high-dose therapy and an autologous stem cell transplant. Data from the Phase III TOURMALINE-MM3 trial will be submitted to regulatory agencies and will be presented at the American Society of Hematology's annual meeting later this year.
Israel-based medical devices startup Sight Diagnostics has released in Europe the OLO point-of-care blood diagnostics system, which allows AI-powered blood testing to be done in a doctor's office. The system, which the company hopes to get FDA approval for next year, digitizes blood into specifically colored microscope images and determines and counts blood cell types using proprietary machine vision algorithms.
UK researchers found Ebola survivors from Sierra Leone had lingering psychiatric and neurological problems, including depression, anxiety, debilitating migraines, nerve pain and strokes. The findings, based on more than 300 Ebola survivors, were published in the journal Emerging Infectious Diseases.
GlaxoSmithKline's investigational drug tafenoquine was found to be generally safe, effective and well-tolerated among malaria patients 16 and older, with data indicating the regimen induced a statistically significant treatment effect for Plasmodium vivax malaria, based on briefing documents the FDA disclosed before an advisory committee meeting. However, FDA researchers did note some concerns regarding the drug's safety in patients with anemia.